Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Table 2 EGFR Gene mutation status

Abbreviations: del stands for deletion; delins stands for deletion-insertion
^a Two patients had double mutation
^b One patient had G719A and 19 del; one patient had G719A and L858R
^c Mutation of exon 21 in Erlotinib Group and Gefinitib Group (45.4% vs 56.7%, P = 0.067)
^d Mutation of exon 19 in Erlotinib Group and Gefinitib Group (52.8% vs 42.1%, P = 0.086)

ISSN: 1471-2407